STAT+: FDA rejects Regenxbio’s rare-disease gene therapy

The Food and Drug Administration has rejected a rare-disease gene therapy from Regenxbio, the company said Monday. 

The one-time treatment, called RGX-121, is designed to replace a malfunctioning gene that causes mucopolysaccharidosis type II, also known as Hunter syndrome, an ultra-rare disorder that causes physical and cognitive impairments. 

Regenxbio had applied for accelerated approval, a type of conditional market clearance, based on RGX-121’s ability to significantly reduce in the short term a specific biomarker in cerebrospinal fluid believed to correlate with longer-term cognitive improvements in patients with the severe form of Hunter syndrome. 

Continue to STAT+ to read the full story…